Danaher (NYSE:DHR) Price Target Raised to $254.00

Danaher (NYSE:DHR) had its price target boosted by Robert W. Baird from $246.00 to $254.00 in a report released on Thursday, MarketBeat.com reports. The firm currently has an outperform rating on the conglomerate’s stock.

DHR has been the topic of several other reports. Barclays lifted their price target on shares of Danaher from $255.00 to $260.00 and gave the stock an “overweight” rating in a research note on Thursday. Stifel Nicolaus cut their price objective on shares of Danaher from $260.00 to $220.00 and set a “buy” rating for the company in a research note on Wednesday, July 22nd. UBS Group started coverage on shares of Danaher in a report on Wednesday, September 9th. They set a “buy” rating and a $250.00 target price on the stock. Weiss Ratings raised shares of Danaher from a “hold (c-)” rating to a “hold (c)” rating in a report on Wednesday, September 16th. Finally, Royal Bank Of Canada lifted their target price on shares of Danaher from $215.00 to $250.00 and gave the stock an “outperform” rating in a research report on Monday, October 5th. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $242.91.

Danaher Trading Up 0.3%

NYSE DHR opened at $230.36 on Thursday. The company has a quick ratio of 1.25, a current ratio of 1.63 and a debt-to-equity ratio of 0.45. The stock’s 50-day simple moving average is $216.32 and its two-hundred day simple moving average is $197.35. Danaher has a twelve month low of $160.93 and a twelve month high of $242.80. The company has a market capitalization of $162.07 billion, a price-to-earnings ratio of 37.70, a PEG ratio of 2.88 and a beta of 0.76.

Danaher (NYSE:DHR) last posted its quarterly earnings data on Wednesday, October 21st. The conglomerate reported $2.11 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.92 by $0.19. The firm had revenue of $6.55 billion during the quarter, compared to analysts’ expectations of $6.56 billion. Danaher had a return on equity of 11.17% and a net margin of 16.91%. The company’s revenue for the quarter was up 8.3% compared to the same quarter last year. During the same period in the prior year, the business earned $1.89 EPS. Research analysts forecast that Danaher will post 8.59 EPS for the current fiscal year.

Danaher Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be given a dividend of $0.40 per share. This represents a $1.60 annualized dividend and a yield of 0.7%. The ex-dividend date is Wednesday, September 30th. Danaher’s dividend payout ratio (DPR) is presently 26.19%.

Hedge Funds Weigh In On Danaher

Large investors have recently bought and sold shares of the stock. Gunderson Capital Management LLC bought a new position in Danaher during the 3rd quarter valued at approximately $765,000. EP Wealth Advisors LLC purchased a new stake in Danaher in the 2nd quarter worth approximately $3,807,000. Frank Rimerman Advisors LLC grew its position in shares of Danaher by 181.9% in the 3rd quarter. Frank Rimerman Advisors LLC now owns 40,855 shares of the conglomerate’s stock worth $9,051,000 after buying an additional 26,363 shares during the last quarter. Birch Hill Investment Advisors LLC grew its position in shares of Danaher by 9.6% in the 3rd quarter. Birch Hill Investment Advisors LLC now owns 40,549 shares of the conglomerate’s stock worth $8,984,000 after buying an additional 3,553 shares during the last quarter. Finally, Forbes J M & Co. LLP grew its position in shares of Danaher by 141.6% in the 3rd quarter. Forbes J M & Co. LLP now owns 4,276 shares of the conglomerate’s stock worth $947,000 after buying an additional 2,506 shares during the last quarter. 79.05% of the stock is owned by hedge funds and other institutional investors.

More Danaher News

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: Danaher reported third-quarter adjusted earnings of $2.11 per share, above the $1.92 analyst consensus, while revenue reached approximately $6.55 billion. Revenue increased 8.3% year over year, and management raised its full-year 2026 adjusted EPS outlook. Danaher 3Q Net Up Sharply as Company Boosts 2026 Adjusted EPS View
• Positive Sentiment: Analysts raised their valuation targets following the results. TD Cowen and JPMorgan lifted targets to $270, Goldman Sachs raised its target to $275, Stifel increased its target to $260, and Robert W. Baird raised its target to $254. The firms maintained bullish ratings, including Buy, Overweight and Outperform. Danaher Analysts Raise Their Forecasts Following Better-Than-Expected Q3 Earnings
• Positive Sentiment: Management highlighted margin strength, improved execution and an increased focus on innovation and artificial intelligence, factors analysts viewed as supporting a better longer-term outlook. Danaher Earnings Call Highlights Margin Strength, AI Push
• Neutral Sentiment: Despite the earnings beat and higher targets, shares declined in the immediate post-results reaction, suggesting investors may have already priced in much of the improvement. A recent valuation comparison also frames DHR as a stock for investors weighing quality and growth against its relatively elevated valuation. Danaher Q3 Recap: Decent Results, Still A Hold
• Negative Sentiment: Danaher’s new CEO emphasized the need for better execution and innovation. TD Cowen cited tariff pressure and a cautious 2027 outlook, creating uncertainty beyond the raised 2026 guidance and helping explain why the stock did not fully respond to the strong quarterly report. Danaher Posts First Earnings Under New CEO

Danaher Company Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops products, services and solutions for the life sciences, biotechnology and diagnostics markets. Its offerings help researchers, pharmaceutical and biotechnology companies, healthcare providers and other organizations conduct scientific research, develop and manufacture medicines, and diagnose disease.

The company operates through businesses that provide bioprocessing equipment and technologies, laboratory instruments, consumables, analytical tools and clinical diagnostic systems.